Press Release

Veeva Teams With Life Sciences to Offer Industrywide Source for Key Contacts, Information, and Services From Across Companies and Brands


Business Wire India
 

MyVeeva for Doctors app makes it easy for HCPs to access the people and resources they need to better treat patients

Leading companies Boehringer Ingelheim, GSK, Pfizer, Sanofi, and Sobi are among first early adopters
 

To help healthcare professionals (HCPs) get provider and patient resources faster, Veeva Systems (NYSE: VEEV), in partnership with the industry, today introduced MyVeeva for Doctors, a mobile application to make it easy for HCPs to connect with life sciences. MyVeeva gives HCPs the key contacts, information, and services they need from across pharmaceutical and biotech companies and brands – all in one place. Leading companies, including Boehringer Ingelheim, GSK, Pfizer, Sanofi, and Sobi, are among the first early adopters of MyVeeva for Doctors.

 

“Fully leveraging the power of digital access allows us to deliver greater value for HCPs, helping them to transform the lives of the patients they treat,” said Marz Abdulrahman, executive director, customer business solutions, at Boehringer Ingelheim Pharmaceuticals, Inc. “Digital solutions like MyVeeva for Doctors enables BI to make it easier to secure patient resources and connect HCPs to the people they need for collaboration in a single, go to place.”

 

“As a rare disease company, shortening time to identify and treat patients is critical,” said Megan Sullivan, vice president, head of commercial innovation, Sobi Inc. “Giving doctors a convenient, timely way to reach us online or through a mobile app has the potential to make digital more practical and useful for doctors. Sobi aims to simplify the healthcare professional digital experience with MyVeeva for Doctors so they can provide better patient care.”

 

Advanced search capabilities in MyVeeva for Doctors makes it simple to find a person, medicine, or company and connect directly with the right contacts such as reps, MSLs, and reimbursement specialists through compliant real-time messaging or online meetings. HCPs can quickly get information and patient resources or request services such as product samples, copay cards, and vouchers. And companies can link brand, corporate, or other websites and resources from MyVeeva to make getting further information easy.

 

“When getting the right people and resources is easy, more healthcare professionals will connect and interact more often,” said Peter Gassner, founder and CEO of Veeva. “Veeva is teaming with the industry to offer the MyVeeva for Doctors app so HCPs can get what they need to better serve patients, all in one convenient place.”

 

MyVeeva for Doctors is available for early adopters in select markets, including the U.S., the U.K., Ireland, Brazil, Colombia, and Australia, with additional countries to follow in 2021. To learn how MyVeeva for Doctors makes it easy for doctors to get the information they need, visit www.myveeva.com.

 

Additional Information

 

For more on MyVeeva for Doctors, visit: www.myveeva.com
Connect with Veeva APAC on LinkedIn: linkedin.com/company/veeva-systems/apac
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems

 

About Veeva Systems

 

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

 

Forward-looking Statements

 

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

 

 





Source link

Content Protection by DMCA.com

Back to top button

Adblock Detected